These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38917394)

  • 21. Dry age-related macular degeneration: mechanisms, therapeutic targets, and imaging.
    Bowes Rickman C; Farsiu S; Toth CA; Klingeborn M
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(14):ORSF68-80. PubMed ID: 24335072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptability of intravitreal injections in geographic atrophy: protocol for a mixed-methods pilot study.
    Enoch J; Ghulakhszian A; Crabb DP; Dinah C; Taylor DJ
    BMJ Open; 2021 Apr; 11(4):e049495. PubMed ID: 33895721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration.
    Akyol E; Lotery A
    Biologics; 2020; 14():83-94. PubMed ID: 32982165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020.
    Samanta A; Aziz AA; Jhingan M; Singh SR; Khanani AM; Chhablani J
    Asia Pac J Ophthalmol (Phila); 2021 Jan; 10(4):408-416. PubMed ID: 33512911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of choroidal thickness in age-related macular degeneration using spectral-domain optical coherence tomography.
    Manjunath V; Goren J; Fujimoto JG; Duker JS
    Am J Ophthalmol; 2011 Oct; 152(4):663-8. PubMed ID: 21708378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advancements in the treatment of age-related macular degeneration: a comprehensive review.
    Papaioannou C
    Postgrad Med J; 2024 Jun; 100(1185):445-450. PubMed ID: 38330506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outer retinal tubulation formation and clinical course of advanced age-related macular degeneration.
    Arrigo A; Aragona E; Battaglia O; Saladino A; Amato A; Borghesan F; Pina A; Calcagno F; Hassan Farah R; Bandello F; Battaglia Parodi M
    Sci Rep; 2021 Jul; 11(1):14735. PubMed ID: 34282240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emixustat and Lampalizumab: Potential Therapeutic Options for Geographic Atrophy.
    Jack LS; Sadiq MA; Do DV; Nguyen QD
    Dev Ophthalmol; 2016; 55():302-9. PubMed ID: 26501510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Review of Completed and Ongoing Complement Inhibitor Trials for Geographic Atrophy Secondary to Age-Related Macular Degeneration.
    Halawa OA; Lin JB; Miller JW; Vavvas DG
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epimacular brachytherapy for wet AMD: current perspectives.
    Casaroli-Marano RP; Alforja S; Giralt J; Farah ME
    Clin Ophthalmol; 2014; 8():1661-70. PubMed ID: 25210436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration.
    Schmid MK; Thiel MA; Lienhard K; Schlingemann RO; Faes L; Bachmann LM
    Eye (Lond); 2019 Oct; 33(10):1584-1589. PubMed ID: 31043690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.
    Qin S; Dong N; Yang M; Wang J; Feng X; Wang Y
    J Immunol Res; 2021; 2021():9945725. PubMed ID: 34368372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema.
    Shaw LT; Mackin A; Shah R; Jain S; Jain P; Nayak R; Hariprasad SM
    Expert Opin Investig Drugs; 2020 Jun; 29(6):547-554. PubMed ID: 32349559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-related macular degeneration.
    Cheung LK; Eaton A
    Pharmacotherapy; 2013 Aug; 33(8):838-55. PubMed ID: 23580402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age-Related Macular Degeneration: What Do We Know So Far?
    Ma HH; Liutkevičienė R
    Acta Med Litu; 2021; 28(1):36-47. PubMed ID: 34393627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(13):1-22. PubMed ID: 23074517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-33trap-mediated IL-33 neutralization does not exacerbate choroidal neovascularization, but fails to protect against retinal degeneration in a dry age-related macular degeneration model.
    Van Hove I; Van Bergen T; Etienne I; Holgado A; Afonina IS; Beyaert R; Feyen JH; Hu TT
    Exp Eye Res; 2021 Jun; 207():108608. PubMed ID: 33930400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
    Vakharia P; Eichenbaum D
    Curr Opin Ophthalmol; 2024 May; 35(3):165-169. PubMed ID: 38421937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dry age-related macular degeneration: recent progress of therapeutic approaches.
    Kuno N; Fujii S
    Curr Mol Pharmacol; 2011 Nov; 4(3):196-232. PubMed ID: 21545354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current therapeutic developments in atrophic age-related macular degeneration.
    Hanus J; Zhao F; Wang S
    Br J Ophthalmol; 2016 Jan; 100(1):122-7. PubMed ID: 26553922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.